Screener Summaries Updates Institutions Sign In More Updates › Other Events › NVCR Other Events · Jun 5, 2026
NovoCure Limited held its annual general meeting of shareholders on June 3, 2026, where eleven directors were elected… NVCR NovoCure Ltd
NovoCure Limited held its annual general meeting of shareholders on June 3, 2026, where eleven directors were elected to terms expiring in 2027. Shareholders also ratified the appointment of Kost Forer Gabbay & Kasierer as independent auditors and approved the company's Amended and Restated 2024 Omnibus Incentive Plan.
More from NovoCure Ltd NovoCure reports Q3 net revenue of $193 million, raises full-year guidance to $736M-$743M Oct 29, 2026 Japan approves NovoCure's Optune Pax for unresectable locally advanced pancreatic cancer Oct 1, 2026 Timothy Scannell retired from the Board of NovoCure Limited effective September 2, 2026 Sep 9, 2026 Novocure reported second quarter 2026 net revenues of $183.6 million, a 16% year-over-year increase, driven by global… Jul 23, 2026 On June 30, 2026, NovoCure announced that its Optune Pax device received a CE Mark for treating adult patients with… Jun 30, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
